No information is available on the clinical use of tucatinib during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during tucatinib therapy and for 1 week after the last dose. However, tucatinib is used in combination with trastuzumab and capecitabine. It is recommended that breastfeeding be suspended for 7 months after the use of trastuzumab.